A Phase 1 interventional study of INT-210 Capsule and INT-210 Capsule in IBD (Inflammatory Bowel Disease), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 33rd largest by enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 13 in phase 1, and was the 106th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9
First in 2009; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 60 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 114 have an industry lead sponsor. The 10 most frequent:
Innatus Therapeutics (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Innatus Therapeutics (Shanghai) Co., Ltd. has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers.
Primary Objectives:
● To assess the safety and tolerability of single and multiple oral dose of INT-210 capsules in healthy adult voluteers,
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Ascending Dose
Drug: INT-210 Capsule
Drug: INT-210 Capsule
BID
Drug: INT-210 Capsule
Placebo for SAD, MAD and Food Effect
Drug: INT-210 Placebo
400 mg INT-210; Oral administration
Escalating doses of 50, 100, 200, 400, 600, 800 mg of INT-210; Single dose administration; Oral administration
Escalating doses of 200, 400, 600 mg of INT-210; BID; Oral administration
INT-210 Placebo BID
The incidence of treatment-emergent adverse events
Number of participants with treatment-related adverse events as assessed. The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity.
Time frame: From Day 1 through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematology
Hemoglobin, Hematocrit, Erythrocytes, Mean corpuscular volume, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation
Activated partial thromboplastin time, Prothrombin time, International Normalized Ratio, Fibrinogen
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistry
Glucose, Blood urea nitrogen, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Phosphate, Bilirubin, total and direct, Alkaline phosphatase, Aspartate transaminase (=SGOT), Alanine transaminase (=SGPT), Gamma glutamyl transferase, Total protein, Albumin, Creatine kinase, Lactate dehydrogenase (LDH)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysis
Specific gravity, PH, Glucose, Protein, Nitrite , Urobilinogen, Occult Blood, White blood cells, Ketones, Red blood cells
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)
ECG assessment (QTcF) as determined by the Investigator/consulting board-certified cardiologist
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in vital signs: hemoglobin saturation (%)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)
Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Pharmacokinetics parameter: Cmax of INT-210
Maximum observed plasma concentration (ng/mL)
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: Tmax of INT-210
Time of maximum observed concentration (Tmax) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: AUC (0-T) of INT-210
Area Under the concentration-time curve from dosing to the time of the last measured concentration (AUC0-T) (h\*ng/L) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: T1/2 of INT-210
Half-life (T1/2) (hours) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: CL/F of INT-210
Apparent clearance (L/h) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: Vz/F of INT-210
Apparent volume of distribution (L) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Pharmacokinetics parameter: AUCinf of INT-210
Area under the curve from time 0 extrapolated to infinite time (AUCinf) (h\*ng/L) of INT-210
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Potential risk of QT/QTc interval prolongation of INT-210
A correlation model will be constructed using drug concentrations and ECG parameters to analyze the concentration-QTc relationship, and the potential risk of QT/QTc interval prolongation will be assessed by establishing a "concentration-effect model".
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Fraction excreted: Fraction of drug excreted unchanged in urine and Feces
Fraction of dose excreted unchanged into urine and feces as a percentage (%)
Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11
Ran from Sep 2025 to primary completion in Jan 2026, 4 months.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 4 months is below that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innatus Therapeutics (Shanghai) Co., Ltd.